Presentation
Jane Lowe
Hello, everyone, and welcome to the Lumos Diagnostics investor briefing to discuss the Q3 FY ’26 results that were lodged with the ASX yesterday. My name is Jane Lowe, and I’ll be your moderator for this session.
With us this morning we have Lumos Diagnostics Chairman, Sam Lanyon. I’ll say good morning to you, Sam.
Samuel Lanyon
Good morning, Jane.
Jane Lowe
Also CEO and Managing Director, Douglas Ward, afternoon to you.
Douglas Ward
CEO, MD & Director
Good morning.
Jane Lowe
And also CFO, Barrie Lambert. Good morning, Barrie.
Barrie Lambert
Chief Financial Officer
Good morning, Jane. Good morning, everyone.
Jane Lowe
Okay. So the format for today is that Sam, Doug and Barrie will walk us through a presentation that was released to ASX this morning, should take about half an hour or so. And after that, we’ll follow on with a Q&A session. We plan to wrap up in about 45 minutes today.
If you’d like to ask a question, please click on the Q&A tab in the ribbon at the bottom of your screen and type your question into the box provided. The webinar is being recorded today as usual.
So with that, I’d now like to hand over to Doug, who will get us on the road. Thanks, Doug.
Douglas Ward
CEO, MD & Director
Thanks very much, Jane. I really appreciate that. Welcome, everyone. As always, it’s always thrilling to speak to our investors and give you an update on the business. We obviously have an updated picture that all 3 of us will go through. I’ll do
